| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3328704 | Critical Reviews in Oncology/Hematology | 2015 | 19 Pages |
Abstract
Pancreatic ductal adenocarcinoma is a malignancy with a poor prognosis, with the majority of patients diagnosed with advanced disease on presentation. Treatment options remain limited with little progress over the last 40 years. This review will focus on the current management of metastatic pancreatic ductal adenocarcinoma, with a discussion of new and future treatment strategies based on an improved understanding of tumour biology and mechanisms of pathogenesis.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Francesco Sclafani, Ridhima Iyer, David Cunningham, Naureen Starling,